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Background: Selective estrogen receptor modulators (SERMs), similar to estrogens, possess vasoprotective effects by
reducing release of reactive oxygen species. Little is known about the potential effects of SERMs on the pathogenesis of
abdominal aortic aneurysms (AAAs). This study’s objective was to investigate the growth of experimental AAAs in the
setting of the SERM tamoxifen.
Methods: In the first set of experiments, adult male rats underwent subcutaneous tamoxifen pellet (delivering 10
mg/kg/day) implantation (n  14) or sham operation (n  16). Seven days later, all animals underwent pancreatic
elastase perfusion of the abdominal aorta. Aortic diameters were determined at that time, and aortas were harvested 7 and
14 days after elastase perfusion for immunohistochemistry, real-time polymerase chain reaction, Western blot analysis,
and zymography. In the second set of experiments, a direct irreversible catalase inhibitor, 3-amino-1,2,4-triazole (AT),
was administered intraperitoneally (1 mg/kg) daily to tamoxifen-treated (n 6) and control rats (n 6), starting on day
7 after elastase perfusion. Aortic diameters were measured on day 14. In a third set of experiments, rats were perfused
with catalase (150 mg/kg) after the elastase (n  5), followed by daily intravenous injections of catalase (150
mg/kg/day) administered for 10 days. A control group of rats (n  7) received 0.9% NaCl instead of catalase.
Results:Mean AAA diameters were approximately 50% smaller in tamoxifen-treated rats compared with sham rats 14 days after
elastase perfusion (P .002). The tamoxifen-treated group’s aortas had a five-fold increase in catalase mRNA expression (P
.02) on day 7 and an eight-fold increase in catalase protein on day 14 (P  .04). Matrix metalloprotroteinase-9 activity was
2.4-fold higher (P  .01) on day 7 in the aortas of the controls compared to the tamoxifen-treated group’s aortas.
Tamoxifen-treated rats had approximately 40% fewer aortic polymorphonuclear neutrophils compared to controls on day 7 (P
 .05). Administration of the direct catalase inhibitor AT to tamoxifen-treated rats partially reversed the aneurysm inhibitory
effect of tamoxifen by nearly 30% (P .02). In contrast, catalase administration inhibited AAA formation by 44% (P .002).
Conclusions:The selective estrogen receptor modulator tamoxifen inhibits the development of AAAs in male rats in association
with an up-regulation of catalase and inhibition of aortic wall neutrophil infiltration. (J Vasc Surg 2005;41:108-14.)
Clinical relevance: A group of medications with estrogen-like properties, the SERMs, act as either an estrogen receptor
agonist or antagonist in a tissue-selective manner. SERM use has increased rapidly because they have been found to be
beneficial in treatment of breast cancer, prevention of osteoporosis, and treatment of desmoid tumors and retroperitoneal
fibrosis. The effects of SERMs on the formation of experimental AAAs have not been studied to date. This study was
designed to determine the effect of tamoxifen on the experimental development of AAAs in a rodent model.Gender differences might be relevant to understanding
the pathogenesis of abdominal aortic aneurysms (AAAs).
Men are more commonly affected than women, with a
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108prevalence ratio of at least 2:1.1,2 This supports the tenet
that female gonadal hormones might protect against AAA
development. We have recently demonstrated that exoge-
nous estrogen administration to male rats before AAA
induction resulted in an approximately 300% reduction in
aneurysm growth.1 Others have reported a similar protec-
tive role of estrogen on experimental AAA formation in
mice.3
A group of medications with estrogen-like properties,
the selective estrogen receptor modulators (SERMs), act as
either an estrogen receptor agonist or antagonist in a
tissue-selective manner. SERM use has increased rapidly
because they have been found to be beneficial in treatment
of breast cancer, prevention of osteoporosis, and treatment
of desmoid tumors and retroperitoneal fibrosis.4 Recent
studies have shown that SERMs, such as tamoxifen and
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ilar to estrogen.5,6 The effects of SERMs on the formation
of experimental AAAs have not been studied to date. This
study was designed to determine the effect of tamoxifen on
the experimental development of AAAs in a rodent model.
Subsequent experiments were performed to demonstrate
the effect of tamoxifen on catalase metabolism and to study
AAA formation after catalase inhibition and supplementa-
tion. In addition, the effect of tamoxifen on aortic wall
inflammatory cell infiltration and metalloproteinase activity
was investigated.
METHODS
Male Sprague-Dawley rats, weighing between 250 and
300 g (Charles River Laboratories, Wilmington, Mass),
were used in all experiments. This study was approved by
the University of Michigan Universal Committee on the
Use and Care of Animals (#8793). Three experiments were
Fig 1. Mean aortic diameter increase (%) compared to preperfu-
sion aortic diameter 7 and 14 days after elastase perfusion. *P 
.002.
Fig 2. Catalase mRNA expression on 7 and 14 days after elastase
perfusion. *P  .02.performed in this investigation.Experiment one. In the first set of experiments, rats
were randomized to receiving implantation of an estrogen
pellet (n 14) or a sham operation (n 16). Implantation
was performed subcutaneously in the posterior neck with a
21-day slow release, 50 mg, tamoxifen free base pellet
(Innovative Research of America, Sarasota, Fla). This pellet
delivers 2.38 mg/day or 10 mg/kg/day of tamoxifen for
21 days. Similar to doses used in the present experiments,
subcutaneous administration of 50 mg slow release tamox-
ifen pellets to rats was shown to result in serum tamoxifen
levels of about 4 ng/g.7 Sham rats underwent the same
procedure without any pellet insertion. Aortas from both
groups were subjected to elastase perfusion 7 days later.
The aortas were then excised for analysis at either 7 or 14
days after elastase perfusion. Pellet absorption was con-
firmed at the time of aortic harvest.
The aneurysm model involved porcine pancreatic elas-
tase perfusion of the abdominal aorta.8 Briefly, the rats were
anesthetized with inhalation 2% to 2.5% isofluorane, and
the infrarenal abdominal aorta was exposed under sterile
conditions. Digital images of the aorta were obtained by
using Spot Insight Color Optical Camera (Diagnostic In-
struments, Inc, Sterling Heights, Mich) attached to an
operating microscope (Nikon, Melville, NY). Aortic diam-
eters were measured by using Image Pro Express (Media
Cybernetics, Inc, Silver Spring, Md). Temporary proximal
and distal aortic control was obtained with a 4-0 cotton
suture loop and Heifetz clamp, respectively. An aortotomy
was made near the aortic bifurcation with a 30-gauge
needle. The infrarenal aorta was cannulated with polyeth-
ylene-10 (PE-10) tubing and perfused for 30 minutes with
6 units of elastase (Lot #083K7655; Sigma, St Louis, Mo)
diluted to a total volume of 1 mL with sterile normal saline.
After perfusion, PE-10 tubing was removed, and the aor-
totomy was closed with 10-0 monofilament suture. At that
time, patency and lower limb perfusion were assured in all
cases, and aortic diameter measurements were repeated.
Aortic harvests occurred on days 7 and 14, after the
aortas were re-exposed andmeasured. Aneurysm formation
was defined as a 100% increase in aortic diameter compared
Fig 3. Catalase protein change (%) in aortas of tamoxifen-treated
rats relative to control rats. *P  .04.to baseline diameter before elastase perfusion. The excised
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One of the two segments was immediately snap-frozen for
TRIzol extraction (Life Technologies, Carlsbad, Calif) of
mRNA for quantitative real-time polymerase chain reaction
(PCR). The protein layer was then dissolved in 1% sodium
dodecylsulfate for Western blot analysis and substrate gel-
atin zymography. The second segment was used for immu-
nohistochemistry.
Experiment two. In the second set of experiments,
control (n  6) and tamoxifen-treated rats (n  6) were
administered 3-amino 1,2,4-triazole (AT) (Sigma-Adrich,
St, Louis, Mo), 1 mg/kg intraperitoneally daily starting on
day 7 after aortic elastase perfusion. This route and dose of
administration of AT result in significant increases in free
radicals as a result of catalase inhibition.9 Aortic diameters
were measured on day 14.
Experiment three. In the third set of experiments,
Fig 4. Immunohistochemical staining (100 magnifi
treated group (B) 14 days after elastase perfusion.
Fig 5. Gelatin zymography of representative aortic samples 7
days after elastase perfusion. MMP-9 activity is 2.4 times higher in
control rats (C) compared to tamoxifen-treated rats (T), P  .01.
MMP-2 activity is similar in the two groups, P  .37.abdominal aortas (n  5) were perfused with bovine livercatalase 150 mg/kg (2350 units/mg protein; Sigma) after
aortic perfusion with elastase. These rats were also admin-
istered catalase (150 mg/kg/day) intravenously via tail
vein for 10 days after aortic perfusion. A control group of
rats (n  7) received 0.9% NaCl instead of catalase.
Quantitative real-time PCR. PCRwas used to define
the expression of catalase and -actin mRNA. Reverse
transcription was performed with oligo-dT primer and
M-MLV Reverse Transcriptase (both Life Technologies,
Grand Island, NY) at 94° C for 3 minutes followed by 40°
C for 70 minutes. The resultant cDNA was amplified by
Taq Polymerase (Promega,Madison,Wis) in a SmartCycler
quantitative PCR system (Cepheid, Sunnyvale, Calif).
SYBR intercalating dye (Roche, Indianapolis, Ind) was
used to monitor cDNA amplification for each gene. Cata-
lase and -actin primer sequences were derived by using
Primer Premier software (PREMIERBiosoft International,
Palo Alto, Calif) based on primary cDNA sequences from
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/).
The primer sequences were 5=-ACTCAGGTGCGGA-
CATTC-3= (catalase sense), 5=- GGAGTTGTACTGGTC-
CAGAAGAGCC-3= (catalase antisense), 5=-ATGGGT-
CAG AAGGATTCCTATGTG-3= (-actin sense), 5=-
CTTCATGAGGTA GTCAGTCAGGTC-3= (-actin
antisense).
Results were normalized by using -actin to correct for
variation in mRNA amounts. Quantification of mRNA
levels used Ct values, calculated by the formula, Ct 
Ct target gene – Ct -actin. Expression of the target gene in
ratio to -actin expression was calculated by the formula,
Target gene expression/-actin expression  2–(Ct).
Western blot analysis. Proteins were separated elec-
trophoretically on a 10% sodium dodecylsulfate–polyacryl-
amide gel electrophoresis and blotted to nitrocellulose
membranes (Biorad, Hercules, Calif). Nonspecific binding
was blocked by membrane incubation for 1 hour in 20
mmol/L Tris-buffered solution followed by 5% nonfat
milk. Rabbit anti-bovine liver polyclonal antibody to cata-
) for catalase (arrows) in control (A) and tamoxifen-cationlase was used (Lot #21748; Abcam, Cambridge, Mass).
ic wal
rfusio
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dase-coupled secondary antibodies and an ECL chemilu-
minesence detection kit (Amersham, Piscataway, NJ). Each
protein band was quantified by densitometry. Similarly,
actin Western blot analyses were performed with a mouse
anti-chicken antibody (cross-reacting with rats) to panactin
(Lot #8793; Neomarkers, Fremont, Calif).
Substrate gel zymography. Zymography was used to
assay matrix metalloproteinase (MMP) activity in the ex-
tracted protein (Novex, San Diego, Calif) as previously
described.10 The relative molecular weight of each band
was determined by comparison of the bands against
MMP-2 andMMP-9 standards (Oncogene Research Prod-
ucts, Boston, Mass). MMP activity was measured by den-
Fig 6. PMNs and macrophage counts in the aort
Fig 7. Anti-PMN antibody staining (100 magnificati
and tamoxifen-treated (B) aortas 7 days after elastase pesitometry.Densitometry. Western blots and zymograms were
imagedwith a FOTO/Analyst CCDCAMERA (Fotodyne,
Hartland, Wis) and quantified by using GEL-Pro Analyzer
software version 3.1 (Media Cybernetics). Optical densities
were normalized to panactin and total protein level in
Western blot and zymogram analyses, respectively.
Histologic analysis. Histologic analysis was per-
formed in aortic segments fixed in fresh, cold 4% parafor-
maldehyde for 18 hours, followed by immersion in 70%
ethanol for 24 hours. Aortas were then embedded in par-
affin, and 4-m transverse sections were prepared for stain-
ing and examination.
Immunohistochemistry was undertaken after deparaf-
finization, rehydration, and unmasking by using Trilogy
l 7 and 14 days after elastase perfusion. *P  .05.
howing aortic PMN infiltration (arrows) in control (A)
n.on) s(Cell Marque Corp, Hot Springs, Ariz) in a Princess model
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hydrogen peroxide in methanol was used to block endog-
enous peroxidase activity. Immunohistochemistry for poly-
morphonuclear neutrophils (PMNs) was performed after
xylene and ethanol deparaffinization and rehydration.
Staining was performed by using a primary rabbit anti-rat
PMN antibody (Accurate Chemical and Scientific Corpo-
ration, Westbury, NY) and a secondary alkaline phospha-
tase anti-rabbit immunoglobulin G (Vector Laboratories,
Burlingame, Calif). ED-1 mononuclear staining was per-
formed by using a mouse anti-rat ED-1 primary antibody
(Serotec, Raleigh, NC) and anti-mouse immunoglobulin G
Vectastain secondary antibody (Vector Laboratories). In-
flammatory cells were counted by a blinded examiner in an
average of 18 randomly chosen high-power fields (HPF)
per slide (n  3 slides in each group).
Catalase antigen retrieval was done by microwave treat-
ment in 10 mmol/L sodium citrate (pH, 6.0). After cool-
ing for 20 minutes, catalase detection was performed by
using rabbit anti-bovine liver polyclonal antibody to cata-
lase (Lot #21748; Abcam) and a secondary alkaline phos-
phatase anti-rabbit immunoglobulin G (Vector Laborato-
ries). Staining in all cases was performed by using Vector
Red alkaline phosphatase (Vector Laboratories) followed
by hematoxylin QS counterstain (Vector Laboratories).
Data analysis. Data were assessed by nonpaired t test
with statistical significance assigned as P  .05. Statistical
analysis was performed with Prism software (GraphPad
Software, San Diego, Calif). All data are expressed as mean
 standard error.
RESULTS
Experimental AAA formation is attenuated in ta-
moxifen-treated male rats. Preperfusion baseline aortic
diameters were not different between tamoxifen-treated
and control aortas (1.53  0.06 mm vs 1.42  0.03 mm,
Fig 8. Mean aortic diameter increase (%) 14 days after elastase
perfusion in groups with and without catalase inhibitor. *P  .05
in comparison to tamoxifen	AT, control	AT, and control
groups. **P .05 in comparison to tamoxifen and control groups.respectively; P  .15). Seven days after elastase perfusion,the mean increases in aortic diameters were 142% 20% in
the tamoxifen-treated group and 218%  43% in the con-
trol group, which were not statistically different (P  .14,
Fig 1). However, by day 14, tamoxifen-treated rats had
significantly smaller (P  .002) aortic diameters (234% 
37% increase) compared to the control group (434% 30%
increase, Fig 1).
Catalase is increased by tamoxifen treatment.
Catalase mRNA expression was almost five times higher in
the aortas of tamoxifen-treated rats than control rats (P 
.02) 7 days after elastase perfusion (Fig 2). Catalase protein
levels were not statistically different on day 7 (P  .62).
However, by day 14 after elastase perfusion, catalase pro-
tein was eight times greater in the tamoxifen-treated aortas
(P  .04, Fig 3).
Immunohistochemistry revealed sparse catalase stain-
ing in the control group but obvious cytoplasmic catalase
staining of smooth muscle cells in the tamoxifen group on
day 14 after elastase perfusion (Fig 4). MMP-9 activity was
2.4 times higher in the control group on day 7 than in the
tamoxifen-treated group (P .01), whereas MMP-2 activ-
ity was similar in the two groups (P  .37, Fig 5). MMP-9
and MMP-2 activity was similar in the two groups on day
14 (P  .7).
Immunohistochemical changes revealed inflamma-
tion within the aneurysmal aortic wall. Aneurysmal aor-
tas exhibited destruction and loss of the internal elastic
medial lamellar structure at 7 and 14 days after elastase
perfusion in both tamoxifen-treated and control rats (data
not shown). However, at 7 days, PMN cell infiltration was
less prominent in the aortic wall of the tamoxifen-treated
rats (26  3.3 cells/HPF) compared to control rats (41 
5.2 cells/HPF, P  .05, Figs 6 and 7). Mononuclear cell
infiltration was not different in the two groups at 7 days (17
 1.0 cells/HPF in the tamoxifen group and 16  1.0
cells/HPF in the control group, P .47). By day 14, both
PMN and macrophage counts were similar in the two
groups (P  .05).
Catalase suppression increased AAA growth com-
pared to catalase supplementation. In the second set of
experiments, the tamoxifen-treated rats that received AT,
the catalase inhibitor, were found to have a 110% greater
increase in aortic diameter (P  .02) at 14 days compared
to the tamoxifen-treated rats not given AT (Fig 8). How-
ever, the increased aortic diameters in tamoxifen-treated
rats that received AT were still 90% less (P  .03) than the
aortic diameters in control rats not given AT, suggesting
that AT only partially reverses the aneurysm inhibitory
effect of tamoxifen. Western blot analysis showed a three-
fold increase in expression of catalase in tamoxifen-treated
rats that received AT compared to control rats that also
received AT (P  .003, Fig 9). In the third set of experi-
ments, catalase-treated rats formed smaller aneurysms than
control rats (189% 18% vs 336% 26%, P .01, Fig 10).
DISCUSSION
Tamoxifen appears to have a partial inhibitory effect on
aneurysmal dilatation in an experimental rodent AAA
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the formation of experimental AAAs is not known. Two
possibilities deserve further consideration.
First, tamoxifen treatment increases catalase within the
aortic wall. Catalase, a potent enzyme involved in hydrogen
peroxide (H2O2) metabolism, is produced by endothelial
and smooth muscle cells.11 Reactive oxygen species, like
H2O2, are known to have an important role in the patho-
genesis of endothelial dysfunction and initiation of certain
vascular diseases.12-16 H2O2 has been noted to activate
vascular smooth muscle cell MMP-2, an enzyme believed
to be important in the formation of AAAs.17,18 Further-
more, the activation of MMP-2 by H2O2 is blocked by
addition of catalase to smoothmuscle cells.17 In the current
study, diminished AAA formation might well have been
mediated via increased reduction of H2O2 as a result of
catalase produced by smooth muscle cell. These data sug-
gest that other reactive oxygen species might also be af-
fected by tamoxifen. This is further supported by the ob-
servation that inhibiting catalase selectively only partially
increased AAA formation, suggesting additional factors
also contribute to AAA pathogenesis. Importantly, catalase
supplementation inhibited aneurysm formation, further
supporting the importance of catalase in experimental AAA
pathogenesis. To our knowledge, the role of catalase in the
pathogenesis of AAAs has not been addressed in other
studies. One study reported increased superoxide levels in
human AAA segments and suggested that H2O2 levels in
AAAs are likely elevated as well.19
Second, the direct antioxidative effects of SERMs are
well established and might affect aneurysm formation. For
example, a metabolite of tamoxifen, 4-hydroxitamoxifen, is
a potent inhibitor of aortic smooth muscle cell membrane
peroxidation by free radicals,6 and administration of the
SERM raloxifen to hypertensive rats results in a marked
decrease in the production of superoxide in aortic seg-
ments.20 SERMs also appear to exert similar protective
effects in other tissues. In this regard, tamoxifen pretreat-
ment reduces ischemic central nervous system damage
Fig 9. Catalase protein change (%) in aortas of tamoxifen	AT–
treated rats relative to control	AT–treated rats. *P  .003.caused by middle cerebral artery occlusion in ovariecto-mized female rats and has been noted to attenuate autoim-
mune nephritis in an autoimmune mouse model.21,22
In addition to the antioxidative effect of tamoxifen
observed in the present study, tamoxifen also resulted in
fewer PMNs and decreased MMP-9 activity in the aortic
wall 7 days after elastase perfusion. Given no difference in
the expression of MMP-9 between the two groups (data
not shown), higher MMP-9 activity in the control group is
speculated to have resulted from a greater release of pre-
formed MMP-9 from PMNs.23
SERMs have been observed to inhibit PMN accumula-
tion in tissues after ischemia reperfusion, which might
contribute to the vascular protective properties of these
agents.24 Furthermore, overexpression of catalase by aortic
endothelial cells is associated with a down-regulation of the
expression of leukocyte adhesion molecules VCAM-1 and
ICAM-1.25 Similarly, estrogen administration in post-
menopausal women decreases serum E-selectin, ICAM-1,
and VCAM-1 levels as compared to those in women who
received placebo.26 These effects on the inflammatory pro-
cess might affect AAA growth.
Macrophages, rather than PMNs, have generally been
regarded as the key inflammatory cells involved in the
pathogenesis of experimental AAAs. However, growing
evidence suggests PMNs also play an important role in the
formation of experimental AAAs. Eliason et al27 reported
that depleting PMNs in a mouse AAA model produces
fewer and smaller experimental AAAs. Recent data from
our laboratory also demonstrated increased L-selectin ex-
pression and PMN infiltration in the aortic wall after elas-
tase perfusion (unpublished data).
This investigation demonstrated a protective role of
tamoxifen on experimental AAA formation. Tamoxifen
up-regulates catalase production and inhibits neutrophil
infiltration in the aortic wall. Tamoxifen, through its effects
on reactive oxygen species and neutrophil infiltration,
might provide a novel therapy for inhibition of AAA
Fig 10. Mean aortic diameter increase (%) 14 days after elastase
perfusion without (control) and with catalase supplementation. *P
 .01.growth.
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